Aristotle Atlantic Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Aristotle Atlantic Partners’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-41,827	Closed	-$993K	–	99
2019 Q4	$993K	Sell	41,827 -9,316	-18%	-$226K	0.13%	73
2019 Q3	$1.41M	Sell	51,143 -40	-0.1%	-$1.19K	0.4%	55
2019 Q2	$1.69M	Buy	51,183 +12	+0%	+$411	0.49%	39
2019 Q1	$1.79M	Buy	51,171 +26,989	+112%	+$1M	0.54%	35
2018 Q4	$803K	Buy	24,182 +3,432	+17%	+$148K	0.28%	55
2018 Q3	$1.04M	Hold	20,750	–	–	0.64%	32
2018 Q2	$1.24M	Buy	20,750 +5,750	+38%	+$298K	0.43%	35
2018 Q1	$687K	Hold	15,000	–	–	0.25%	43
2017 Q4	$598K	Buy	+15,000	New	+$593K	0.21%	42

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Aristotle Atlantic Partners's SUPN Position: Q1 2020 in Review

Aristotle Atlantic Partners sold out of Supernus Pharmaceuticals (SUPN) in Q1 2020, closing a stake of 41,827 shares — an estimated $993K sold.

Aristotle Atlantic Partners first reported a position in SUPN in Q4 2017 and held it in 9 quarters. The position peaked at $1.79M in Q1 2019. 208 funds tracked by Wall St. Rank hold SUPN as of Q1 2020.

Aristotle Atlantic Partners reported no remaining Supernus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Aristotle Atlantic Partners sold 41,827 Supernus Pharmaceuticals shares in Q1 2020, an estimated $993K.
Aristotle Atlantic Partners first reported a position in Supernus Pharmaceuticals in Q4 2017 and held it in 9 quarters.
Aristotle Atlantic Partners's Supernus Pharmaceuticals position peaked at $1.79M in Q1 2019.
208 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2020.

Based on Aristotle Atlantic Partners's 13F filing for Q1 2020, filed 14 May 2020.